Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. Preliminary safety and efficacy data of ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈